Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

ccfDNA Workflows: Honing in on the Target

  • Optimizing purification of ccfDNA
  • Methods for ccfDNA QC and detection of genomic DNA contamination
  • Tips and tricks for removing gDNA contamination to ensure targeted sequencing

Summary

ccfDNA Webinar Series: The Basics and Beyond

Part 2 - ccfDNA Workflows: Honing in on the Target

Circulating cell-free DNA (ccfDNA) is one of the most promising sources of DNA-based information for oncology research available today. Scientists continue to look for better ways to actively target the precious small fragment DNA necessary for liquid biopsy applications.

The low concentration and highly fragmented nature of ccfDNA, coupled with the low frequency of biomarkers of interest, present many challenges to the adoption of ccfDNA monitoring. In this webinar, we will discuss techniques for maximizing ccfDNA results through:

  • Proper sample handling
  • Purification
  • Quantitation
  • QC
  • Downstream processing

Don't forget to check out Part 1 & 3!


Speaker

douglas-horejsh-125x126

Douglas Horejsh, PhD
Senior Research Scientist
Promega Corporation

Douglas Horejsh is a Senior Research Scientist in the Protein and Nucleic Acid Analysis Division of Research & Development at Promega Corporation. He is interested in development of nucleic acid purification systems to yield high quality nucleic acids from challenging starting samples. His group develops purification chemistries in manual and large instrument formats, along with fluorescent dyes for nucleic acid detection.

Prior to joining Promega, Douglas was a clinical lab director for a molecular pathology company in Virginia. His work focused on identification, evaluation, validation, and integration of IVD and LDT assays in a clinical lab setting. He also managed BSL-3 facilities and led research on emerging/biodefense pathogens.

Douglas has authored 20 journal articles and is an inventor of issued world and Italian patents. He received his Ph.D. in 2001 from the University of Wisconsin-Madison and trained as a post-doc at the Institute of Human Virology in Baltimore, MD.

We love to talk science.

Sign up to receive monthly invitations to our webinars.

Sign Up